Last reviewed · How we verify
NCT03394144
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
Phase 1 trial testing AZD9150, Durvalumab in Advanced Solid Malignancies in 11 participants. Completed in 12 April 2019.
12 April 2019
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 30 January 2018 |
| Primary completion | 12 April 2019 |
| Estimated completion | 12 April 2019 |
| Sites | 2 locations across Japan |
Drugs / interventions tested
- AZD9150, Durvalumab — full drug profile →
Conditions studied
- Advanced Solid Malignancies — all drugs for Advanced Solid Malignancies →
Sponsor
AstraZeneca — full company profile →
Who can join
Adults 20 to 120, any sex, with Advanced Solid Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with advanced solid malignancies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumor microenvironment as a therapeutic target in cancer.
Xiao Y, Yu D. · · 2021 · cited 1438× · PMID 33259885 · DOI 10.1016/j.pharmthera.2020.107753 -
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance.
Wang S, Wang J, Chen Z, Luo J, et al · · 2024 · cited 406× · PMID 38341519 · DOI 10.1038/s41698-024-00522-z -
Recent Advances in Oligonucleotide Therapeutics in Oncology.
Xiong H, Veedu RN, Diermeier SD. · · 2021 · cited 132× · PMID 33804856 · DOI 10.3390/ijms22073295 -
STAT3 pathway in cancers: Past, present, and future.
Wang HQ, Man QW, Huo FY, Gao X, et al · · 2022 · cited 123× · PMID 35356799 · DOI 10.1002/mco2.124 -
STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma.
Lee C, Cheung ST. · · 2019 · cited 101× · PMID 31731457 · DOI 10.3390/cancers11111646 -
Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics.
Borlongan MC, Wang H. · · 2023 · cited 30× · PMID 37305676 · DOI 10.3389/fcell.2023.1125174 -
Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.
Nishina T, Fujita T, Yoshizuka N, Sugibayashi K, et al · · 2022 · cited 29× · PMID 36270753 · DOI 10.1136/bmjopen-2021-055718 -
Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation.
Raguraman P, Balachandran AA, Chen S, Diermeier SD, et al · · 2021 · cited 27× · PMID 34771719 · DOI 10.3390/cancers13215555
Verify or expand the search:
- PubMed search for NCT03394144
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Malignancies
Currently open trials in the same condition.
- NCT07223047 — A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent · Phase 1, PHASE2 · recruiting
- NCT06927297 — Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors · Phase 1 · recruiting
- NCT06760481 — Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIG · Phase 1 · active not recruiting
- NCT06899061 — Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saru · Phase 1 · active not recruiting
- NCT05417594 — Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignanc · Phase 1, PHASE2 · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03394144 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 24 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03394144.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing